Form 4: Halozyme Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
James M Daly, a Director of Halozyme Therapeutics, Inc., reported multiple transactions in common stock on October 1, 2026.
Summary
- Grant/award: acquired 1,169 Restricted Stock Units on October 1, 2026; holds 1,169 after (Direct).
- Grant/award: acquired 1,775 Option to Purchase Common Stock on October 1, 2026; holds 1,775 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
James M Daly — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Grant/award | Restricted Stock Units | 1,169 | — | — | 1,169 |
| 2026-10-01 | Grant/award | Option to Purchase Common Stock | 1,775 | — | — | 1,775 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Grant/award (1,169 shares) |
| 2026-10-01 | Grant/award (1,775 shares) |
Keywords
insider transaction, Form 4, HALO, HALOZYME THERAPEUTICS, INC., neutral, James M Daly
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.